Under the agreement, part of Medtronic’s reimbursement will be tied to clinical improvement measures to enhance care quality while lowering medical expenses. The outcomes-based model will affect Aetna members with type 1 and type 2 diabetes who transition to Medtronic’s insulin pump from multiple daily injections.
Some Aetna policyholders will transfer to one Medtronic insulin system, called the MiniMed 670G, which continuously self-adjusts insulin amounts based on a patient’s specific needs.
More articles on payer issues:
4 things to know about BCBSA’s 2016 community health investments
Aetna moving HQs to attract ‘younger people, innovation’
Cigna CEO: 2017 growth could involve Medicare Advantage deals
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
